EN / 中文
您的位置： 首页 > 2021年1月 第52卷 第1期 > 文字全文
2023年7月 第38卷 第7期11
目录

SEER数据库中晚期三阴性乳腺癌的危险因素及预后分析

Analysis of risk factors and prognosis of advanced triple negative breast cancer based on SEER database

来源期刊： 广州医药 | 26-34 发布时间：2021-11-22 收稿时间：2025/11/13 18:13:02 阅读量：25
作者：
叶晔,
费伟强,
冯冠,
关键词：
晚期三阴性乳腺癌列线图SEER数据库生存分析
Triple negative breast cancerNomogramSEER databaseSurvival analysis
DOI：
10.3969/j.issn.1000-8535.2021.01.006
收稿时间：
2020-07-16 
修订日期：
 
接收日期：
 
引用总数：
0  
目的 分析晚期三阴性乳腺癌(TNBC)的危险因素并建立有效的预后列线图。方法 通过检索美国SEER(surveillance, epidemiology, and end results)数据库筛选晚期TNBC患者,采用单因素和多因素分析来确定晚期TNBC的独立预后因素,并以此构建了列线图,通过校准曲线检验和C指数(C-index)评估已建立的列线图。结果 共纳入4 687例晚期TNBC患者,与同期其他分子分型的乳腺癌相比较,TNBC的预后最差。单因素分析发现,年龄、性别、分期、手术、化疗、放疗、转移与更好的预后相关(P<0.05)。多因素分析发现年龄、性别、种族、分期、手术、化疗、放疗、各器官转移是患者预后的独立影响因素(P<0.05),并以此构建了列线图,其C-index为0.75(95％CI,0.71～0.79),校准图显示了预测的总生存期(OS)与观察到的OS之间的最佳一致性。结论 我们分析了晚期TNBC的临床特征,为TNBC患者的OS提供了一些预后因素,并根据这些预后因素制定了列线图,帮助临床医生进行风险管理并选择TNBC患者的长期生存策略。
Objective To analyze the risk factors of advanced triple-negative breast cancer (TNBC) and establish an effective prognostic nomogram. Methods Screening patients with advanced TNBC by searching the SEER (surveillance, epidemiology, and end results) database, using univariate and multivariate analysis to determine the independent prognostic factors of advanced TNBC, and constructing a nomogram based on it. Results A total of 4 687 patients with advanced TNBC were included. Compared with other types of breast cancer over the same period, TNBC had the worst prognosis. Univariate analysis found that age, gender, stage, surgery, chemotherapy, radiotherapy, and metastasis were associated with a better prognosis (P<0.05). Multivariate analysis found that age, gender, race, stage, surgery, chemotherapy, radiotherapy, and metastasis of the organs were independent factors affecting the prognosis of patients (P<0.05), and constructed a nomogram with a C-index of 0.75 ( 95% CI, 0.71～0.79). The calibration chart showed the best agreement between the predicted overall survival (OS) and the observed OS. Conclusion We analyzed the clinical features of advanced TNBC, provided some prognostic factors for the OS of TNBC patients, and developed a nomogram based on these prognostic factors to help clinicians manage risk and choose long-term survival strategies for TNBC patients.
1、 JIANG Z F, CRISTOFANILLI M, SHAO Z M, et al. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial [J]. Ann Oncol, 2013, 24(11): 2766-2772. JIANG Z F, CRISTOFANILLI M, SHAO Z M, et al. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial [J]. Ann Oncol, 2013, 24(11): 2766-2772.
2、 WJEFFREY A, JERI M, MCRAIG M, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J]. Clin Cancer Res, 2004, 10(20): 6897-6904. WJEFFREY A, JERI M, MCRAIG M, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J]. Clin Cancer Res, 2004, 10(20): 6897-6904.
3、 van de STOLPE A, PANTEL K, SLEIJFER S, et al. Circulating tumor cell isolation and diagnostics: toward routine clinical use [J]. Cancer Res, 2011, 71(18): 5955-5960. van de STOLPE A, PANTEL K, SLEIJFER S, et al. Circulating tumor cell isolation and diagnostics: toward routine clinical use [J]. Cancer Res, 2011, 71(18): 5955-5960.
4、 SHEN Z, WU A, CHEN X. Current detection technologies for circulating tumor cells [J]. Chem Soc Rev, 2017, 46(8): 2038-2056. SHEN Z, WU A, CHEN X. Current detection technologies for circulating tumor cells [J]. Chem Soc Rev, 2017, 46(8): 2038-2056.
5、 NICOLINI A, CARPI A, TARRO G. Biomolecular markers of breast cancer [J]. Front Biosci, 2006(11): 1818-1843. NICOLINI A, CARPI A, TARRO G. Biomolecular markers of breast cancer [J]. Front Biosci, 2006(11): 1818-1843.
6、 NICOLINI A, GIARDINO R, CARPI A, et al. Metastatic breast cancer: an updating [J]. Biomed Pharmacother, 2006, 60(9): 548-556. NICOLINI A, GIARDINO R, CARPI A, et al. Metastatic breast cancer: an updating [J]. Biomed Pharmacother, 2006, 60(9): 548-556.
7、 SCULLY O J, BAY B H, YIP G, et al. Breast cancer metastasis [J]. Send to Cancer Genomics Proteomics, 2012, 9(5): 311-320. SCULLY O J, BAY B H, YIP G, et al. Breast cancer metastasis [J]. Send to Cancer Genomics Proteomics, 2012, 9(5): 311-320.
8、 WANG J, SHI M, LING R, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial [J]. Radiother Oncol, 2011, 100(2): 200-204. WANG J, SHI M, LING R, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial [J]. Radiother Oncol, 2011, 100(2): 200-204.
9、 CHEN L, ZHANG J, CHEN J, et al. Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes [J]. Oncotarget, 2017, 8(26): 42917-42925. CHEN L, ZHANG J, CHEN J, et al. Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes [J]. Oncotarget, 2017, 8(26): 42917-42925.
10、 HE M Y, RANCOULE C, REHAILIA-BLANCHARD A, et al. Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies [J]. Crit Rev Oncol Hematol, 2018(131): 96-101. HE M Y, RANCOULE C, REHAILIA-BLANCHARD A, et al. Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies [J]. Crit Rev Oncol Hematol, 2018(131): 96-101.
11、 SHARMA P, LóPEZ-TARRUELLA S, GARCíA-SAENZ JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts [J]. Clin Cancer Res, 2017, 23(3): 649-657. SHARMA P, LóPEZ-TARRUELLA S, GARCíA-SAENZ JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts [J]. Clin Cancer Res, 2017, 23(3): 649-657.
12、 LIEDTKE C, MAZOUNI C, HESS K R, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol, 2008, 26(8): 1275-1281. LIEDTKE C, MAZOUNI C, HESS K R, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol, 2008, 26(8): 1275-1281.
13、 KIM S, PARK H S, KIM J Y, et al. Comparisons of oncologic outcomes between triple-negative breast cancer (tnbc) and non-tnbc among patients treated with breast-conserving therapy [J]. Yonsei Med J, 2016, 57(5): 1192-1198. KIM S, PARK H S, KIM J Y, et al. Comparisons of oncologic outcomes between triple-negative breast cancer (tnbc) and non-tnbc among patients treated with breast-conserving therapy [J]. Yonsei Med J, 2016, 57(5): 1192-1198.
14、 KREIKE B, HALFWERK H, ARMSTRONG N, et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients [J]. Clin Cancer Res, 2009, 15(12): 4181-4190. KREIKE B, HALFWERK H, ARMSTRONG N, et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients [J]. Clin Cancer Res, 2009, 15(12): 4181-4190.
15、 ZAKY S S, LUND M, MAY K A, et al. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy [J]. Ann Surg Oncol, 2011, 18(10):2858-2865. ZAKY S S, LUND M, MAY K A, et al. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy [J]. Ann Surg Oncol, 2011, 18(10):2858-2865.
16、 XING L, HE Q, WANG Y Y, et al. Advances in the surgical treatment of breast cancer [J]. Chin Clin Oncol, 2016, 5(3): 34. XING L, HE Q, WANG Y Y, et al. Advances in the surgical treatment of breast cancer [J]. Chin Clin Oncol, 2016, 5(3): 34.
17、 ADEMUYIWA F O, TAO Y, LUO J, et al. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians [J]. Breast Cancer Res Treat, 2017, 161(3): 491-499. ADEMUYIWA F O, TAO Y, LUO J, et al. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians [J]. Breast Cancer Res Treat, 2017, 161(3): 491-499.
18、 TELONIS A G, RIGOUTSOS I. Race disparities in the contribution of mirna isoforms and trna-derived fragments to triple-negative breast cancer [J]. Cancer Res, 2018, 78(5): 1140-1154. TELONIS A G, RIGOUTSOS I. Race disparities in the contribution of mirna isoforms and trna-derived fragments to triple-negative breast cancer [J]. Cancer Res, 2018, 78(5): 1140-1154.
19、 PARISE C, CAGGIANO V. The influence of marital status and race/ethnicity on risk of mortality for triple negative breast cancer [J]. PLoS One, 2018, 13(4): e0196134. PARISE C, CAGGIANO V. The influence of marital status and race/ethnicity on risk of mortality for triple negative breast cancer [J]. PLoS One, 2018, 13(4): e0196134.
20、 DIETZE E C, SISTRUNK C, MIRANDA-CARBONI G, et al. Triple-negative breast cancer in African-American women: disparities versus biology [J]. Nat Rev Cancer, 2015, 15(4): 248-254. DIETZE E C, SISTRUNK C, MIRANDA-CARBONI G, et al. Triple-negative breast cancer in African-American women: disparities versus biology [J]. Nat Rev Cancer, 2015, 15(4): 248-254.
21、 LIEDTKE C, RODY A, GLUZ O, et al. The prognostic impact of age in different molecular subtypes of breast cancer [J]. Breast Cancer Res Treat, 2015, 152(3):667-673. LIEDTKE C, RODY A, GLUZ O, et al. The prognostic impact of age in different molecular subtypes of breast cancer [J]. Breast Cancer Res Treat, 2015, 152(3):667-673.
22、 LIEDTKE C, HESS K R, KARN T, et al. The prognostic impact of age in patients with triple-negative breast cancer [J]. Breast Cancer Res Treat, 2013, 138(2): 591-599. LIEDTKE C, HESS K R, KARN T, et al. The prognostic impact of age in patients with triple-negative breast cancer [J]. Breast Cancer Res Treat, 2013, 138(2): 591-599.
23、 BEADLE B M, WOODWARD W A, BUCHHOLZ T A. The impact of age on outcome in early-stage breast cancer [J]. Semin Radiat Oncol, 2011, 21(1): 26-34. BEADLE B M, WOODWARD W A, BUCHHOLZ T A. The impact of age on outcome in early-stage breast cancer [J]. Semin Radiat Oncol, 2011, 21(1): 26-34.
24、 ROMAGNOLO A P, ROMAGNOLO D F, SELMIN O I. BRCA1 as target for breast cancer prevention and therapy [J]. Anticancer Agents Med Chem, 2015,15(1): 4-14. ROMAGNOLO A P, ROMAGNOLO D F, SELMIN O I. BRCA1 as target for breast cancer prevention and therapy [J]. Anticancer Agents Med Chem, 2015,15(1): 4-14.
25、 CHEN H, WU J, ZHANG Z, et al. Association between brca status and triple-negative breast cancer: a meta-analysis [J]. Front Pharmacol, 2018( 9): 909. CHEN H, WU J, ZHANG Z, et al. Association between brca status and triple-negative breast cancer: a meta-analysis [J]. Front Pharmacol, 2018( 9): 909.
26、 HURVITZ S, MEAD M. Triple-negative breast cancer: advancements in characterization and treatment approach [J]. Curr Opin Obstet Gynecol, 2016, 28(1): 59-69. HURVITZ S, MEAD M. Triple-negative breast cancer: advancements in characterization and treatment approach [J]. Curr Opin Obstet Gynecol, 2016, 28(1): 59-69.
27、 LI X, YANG J, PENG L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer [J]. Breast Cancer Res Treat, 2017, 161(2):279-287. LI X, YANG J, PENG L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer [J]. Breast Cancer Res Treat, 2017, 161(2):279-287.
28、 AGARWAL G, NANDA G, LAL P, et al. Outcomes of triple-negative breast cancers (tnbc) compared with non-tnbc: does the survival vary for all stages? [J]. World J Surg, 2016, 40(6): 1362-1372. AGARWAL G, NANDA G, LAL P, et al. Outcomes of triple-negative breast cancers (tnbc) compared with non-tnbc: does the survival vary for all stages? [J]. World J Surg, 2016, 40(6): 1362-1372.
29、 YANG Y, WANG Y, DENG H, et al. Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer [J]. BMC Cancer, 2019, 19(1): 541. YANG Y, WANG Y, DENG H, et al. Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer [J]. BMC Cancer, 2019, 19(1): 541.
30、 GUO L W, JIANG L M, GONG Y, et al. Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer [J]. Cancer Manag Res, 2018(10): 5881-5894. GUO L W, JIANG L M, GONG Y, et al. Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer [J]. Cancer Manag Res, 2018(10): 5881-5894.
31、 LIN Y, FU F, LIN S, et al. A nomogram prediction for the survival of patients with triple negative breast cancer [J]. Oncotarget, 2018, 9(63):32108-32118. LIN Y, FU F, LIN S, et al. A nomogram prediction for the survival of patients with triple negative breast cancer [J]. Oncotarget, 2018, 9(63):32108-32118.
32、 FAN L, STRASSER-WEIPPL K, LI J J, et al. Breast cancer in China [J]. Lancet Oncol, 2014, 15(7): e279-289. FAN L, STRASSER-WEIPPL K, LI J J, et al. Breast cancer in China [J]. Lancet Oncol, 2014, 15(7): e279-289.
33、 CHEN W, ZHENG R, BAADE PD,et al. Cancer Statistics in China, 2015 [J]. Cancer J Clin, 2018, 68(1):7-30. CHEN W, ZHENG R, BAADE PD,et al. Cancer Statistics in China, 2015 [J]. Cancer J Clin, 2018, 68(1):7-30.
34、 JIN C, CAO J, CAI Y, et al. A nomogram for predicting the risk of invasive pulmonary adenocarcinoma for patients with solitary peripheral subsolid nodules [J]. J Thorac Cardiovasc Surg, 2017, 153(2):462-469. JIN C, CAO J, CAI Y, et al. A nomogram for predicting the risk of invasive pulmonary adenocarcinoma for patients with solitary peripheral subsolid nodules [J]. J Thorac Cardiovasc Surg, 2017, 153(2):462-469.
35、 IASONOS A, SCHRAG D, RAJ GV, et al. How to build and interpret a nomogram for cancer prognosis [J]. J Clin Oncol, 2008, 26(8):1364-1370. IASONOS A, SCHRAG D, RAJ GV, et al. How to build and interpret a nomogram for cancer prognosis [J]. J Clin Oncol, 2008, 26(8):1364-1370.
36、 KUMAR P, AGGARWAL R. An overview of triple-negative breast cancer [J]. Arch Gynecol Obstet, 2016, 293(2): 247-269. KUMAR P, AGGARWAL R. An overview of triple-negative breast cancer [J]. Arch Gynecol Obstet, 2016, 293(2): 247-269.
37、 KARAAYVAZ M, CRISTEA S, GILLESPIE SM, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq [J]. Nat Commun, 2018, 9(1):3588. KARAAYVAZ M, CRISTEA S, GILLESPIE SM, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq [J]. Nat Commun, 2018, 9(1):3588.
38、 WEIN L, LOI S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC) [J]. Breast, 2017, 34(1): S27-S30. WEIN L, LOI S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC) [J]. Breast, 2017, 34(1): S27-S30.
39、 NAGINI S. Breast cancer: current molecular therapeutic targets and new players [J]. Anticancer Agents Med Chem, 2017, 17(2):152-163. NAGINI S. Breast cancer: current molecular therapeutic targets and new players [J]. Anticancer Agents Med Chem, 2017, 17(2):152-163.
40、 JHAN J R, ANDRECHEK E R. Triple-negative breast cancer and the potential for targeted therapy [J]. Pharmacogenomics, 2017, 18(17):1595-1609. JHAN J R, ANDRECHEK E R. Triple-negative breast cancer and the potential for targeted therapy [J]. Pharmacogenomics, 2017, 18(17):1595-1609.
41、 LI X, YANG J, PENG L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer [J]. Breast Cancer Res Treat, 2017, 17(2): 152-163. LI X, YANG J, PENG L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer [J]. Breast Cancer Res Treat, 2017, 17(2): 152-163.
42、 WU Q, LI J, ZHU S, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study [J]. Oncotarget, 2017, 8(17): 27990-27996. WU Q, LI J, ZHU S, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study [J]. Oncotarget, 2017, 8(17): 27990-27996.
43、 ABRAMSON V G, LEHMANN B D, BALLINGER T J, et al. Subtyping of triple-negative breast cancer: implications for therapy [J]. Cancer, 2015, 121(1): 8-16. ABRAMSON V G, LEHMANN B D, BALLINGER T J, et al. Subtyping of triple-negative breast cancer: implications for therapy [J]. Cancer, 2015, 121(1): 8-16.
44、 CAMORANI S, FEDELE M, ZANNETTI A, et al. TNBC Challenge: oligonucleotide aptamers for new imaging and therapy modalities [J]. Pharm (Basel), 2018, 11(4):E123. CAMORANI S, FEDELE M, ZANNETTI A, et al. TNBC Challenge: oligonucleotide aptamers for new imaging and therapy modalities [J]. Pharm (Basel), 2018, 11(4):E123.
45、 SIEGEL R L, MILLER K D, JEMAL A, et al. Cancer statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(1):7-34. SIEGEL R L, MILLER K D, JEMAL A, et al. Cancer statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(1):7-34.
上一篇
下一篇
作者登录
作者注册
审稿登录
编辑登录
最新资讯

“胶质瘤精准诊疗”专题征稿启事

发布于: 2026-05-29

“精神心理与脑科学：前沿与实践”专题征稿启事

发布于: 2026-05-29

“人工智能与医学融合”专题征稿启事

发布于: 2025-02-19

征稿 |《广州医药》—“医院管理”专栏征稿

发布于: 2025-01-21
学术活动

会议通知|人工智能赋能学科高质量发展专题讲座

发布于: 2025-02-19

广州市第一人民医院烧伤整形美容与创面修复科举办首期EWMA创面管理与修复培训班

发布于: 2026-05-29

提质增效，创新作为，不断提升麻醉服务能力2024工作总结与2025工作计划

发布于: 2025-02-19

2026年广州市医学会血液学分会学术年会暨再生障碍性贫血研讨会圆满落幕

发布于: 2026-06-01
出版者信息






《广州医药》公众号
目录
友情链接
关注微信公众号
首页   | 关于我们   | 联系我们  粤ICP备17084739号-3
关注微信公众号
粤ICP备17084739号-3